DiscoverTalking Points
Talking Points
Claim Ownership

Talking Points

Author: TCTMD

Subscribed: 49Played: 646
Share

Description

A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe.
06f763f0-76e5-11f0-bb7c-8557ae1d8a8b
203 Episodes
Reverse
How has the pharmacotherapy for STEMI changed over the past 46 years? Ginger Jiang and C. Michael Gibson discuss treating patients with zalunfiban at first medical contact.
The CorCMR Trial

The CorCMR Trial

2026-03-0405:50

Colin Berry and C. Michael Gibson discuss whether stress CMR imaging is helpful in patients with angina and no obstructive CAD.
The TUXEDO-2 Trial

The TUXEDO-2 Trial

2026-02-0403:56

Sripal Bangalore and C. Michael Gibson discuss whether ticagrelor is noninferior to prasugrel in patients with diabetes and multivessel CAD undergoing PCI.
The FLOW Trial

The FLOW Trial

2026-01-0705:33

C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.
Mamas Mamas, Nieves Gonzalo, and Erick Schampaert take a look at the latest guidelines for chronic coronary syndromes and how they relate to complex PCI.
Thomas Crawford meets with C. Michael Gibson to discuss the role of reconditioned pacemakers in low- and middle-income countries.
Mamas Mamas, Birgitte Krogsgaard Andersen, and Niels Ramsing Holm discuss QFR versus FFR for guiding resvascularization in patients with coronary stenoses.
The FLOW Trial

The FLOW Trial

2025-12-0305:33

C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.
STORM-PE TRIAL

STORM-PE TRIAL

2025-11-1914:24

James Benenati, Robert Lookstein, and Rachel Rosovsky discuss the STORM-PE trial, the first-of-its-kind RCT for acute intermediate-high risk pulmonary embolism (PE).
For patients with aortic stenosis, is earlier intervention beneficial? Mamas Mamas, Philippe Généreux, Nicolas Van Mieghem, and Bernard Prendergast discuss.
The EPIC-CAD Trial

The EPIC-CAD Trial

2025-10-2914:27

Mamas Mamas and Gi-byoung Nam discuss edoxaban monotherapy in patients with high-risk AF and stable CAD.
The ECLIPSE Trial

The ECLIPSE Trial

2025-10-0107:38

Ajay Kirtane and C. Michael Gibson discuss how orbital atherectomy compares with balloon angioplasty for severely calcified coronary arteries before DES implantation.
Does long-term colchicine benefit patients after acute MI? C. Michael Gibson and Sanjit Jolly discuss. 097245
The NOTION-3 Trial

The NOTION-3 Trial

2025-09-0317:21

Mamas Mamas talks to Jacob Thomsen Lønborg about how PCI affects outcomes for patients with stable CAD undergoing TAVI.
Transcatheter devices are new to the heart failure (HF) community and treatment armamentarium for severe MR. This discussion focuses on the impact of transcatheter devices on HF patients and current barriers faced by referring specialists.
The ABYSS Trial

The ABYSS Trial

2025-08-1306:02

Johanne Silvain, Gilles Montalescot, and C. Michael Gibson discuss the effects of beta-blocker interruption in post-MI patients.
Patient selection is important for transcatheter interventions and impacts result success. This discussion focuses on defining what treatment goals should be, limitations of current interventions, and identifying appropriate transcatheter patients.
Paul Ridker and C. Michael Gibson discuss 30-year data hinting at how three modifiable factors—LDL, hs-CRP, and Lp(a)—might be leveraged to reduce long-term risk. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b
Clinical trials face challenges with variability in echo images, protocol adherence, and data quality. This discussion focuses on strategies to improve trial integrity, operational efficiency, and regulatory approval of transcatheter devices.
The Intrepid TMVR system just released 2-year transfemoral EFS outcomes at NY Valves. This discussion provides a deeper dive into what this data means for the Intrepid mitral program and perspectives on the transcatheter landscape.
loading
Comments 
loading